Dn B Asset Management As Nektar Therapeutics Transaction History

Dn B Asset Management As

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 Apr 17, 2020	SELL	$14.47 - $27.96 $646,780 - $1.25 Million	-44,698 Closed	0 $0
Q4 2019 Jan 13, 2020	BUY	$15.87 - $23.12 $415,397 - $605,166	26,175 Added 141.31%	44,698 $965,000
Q3 2019 Oct 16, 2019	BUY	$16.91 - $36.27 $8,150 - $17,482	482 Added 2.67%	18,523 $337,000
Q2 2019 Jul 08, 2019	BUY	$31.0 - $36.3 $19,158 - $22,433	618 Added 3.55%	18,041 $0
Q1 2019 Apr 11, 2019	SELL	$31.58 - $46.35 $83,023 - $121,854	-2,629 Reduced 13.11%	17,423 $0
Q4 2018 Jan 15, 2019	SELL	$30.43 - $56.65 $1,734 - $3,229	-57 Reduced 0.28%	20,052 $659,000
Q3 2018 Oct 10, 2018	BUY	$46.46 - $68.49 $181,612 - $267,727	3,909 Added 24.13%	20,109 $0
Q2 2018 Jul 06, 2018	BUY	$46.25 - $104.45 $749,250 - $1.69 Million	16,200 New	16,200 $0

140

135M

32.8K

55.5K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $246M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Dn B Asset Management As, based on Form 13F filings with the SEC.

Stay updated on Dn B Asset Management As with notifications on news.